Docetaxel accumulates in lymphatic circulation following subcutaneous delivery compared to intravenous delivery in rats

Deanna R. Worley, Ryan J. Hansen, Luke Anthony Wittenburg, Laura S. Chubb, Daniel L. Gustafson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The circulatory pathway for particles deposited outside of blood capillaries has not been well characterized for non-traditionally-delivered chemotherapeutics. Materials and Methods: Blood and lymph pharmacokinetics of docetaxel (5 mg/kg) and carboplatin (14 and 28 mg/kg) following subcutaneous (s.c.) versus intravenous (i.v.) delivery were determined in a rodent model with catheterizations of both the thoracic lymphatic duct and jugular vein for prolonged synchronous blood and lymph sampling. Results: Subcutaneous docetaxel demonstrates preferential lymphatic accumulation based on the area under the time-concentration curve (AUC0-24h) whereas i.v. docetaxel resulted in a greater plasma maximum concentration measured (Cmax). The apparent elimination half-life (t1/2) in lymph for docetaxel is greater following i.v. or s.c. delivery compared to t1/2 in blood. Carboplatin demonstrates a dose-dependent increase in plasma Cmax regardless of delivery route; the total carboplatin exposure over 24 h in lymph and plasma are comparable. Conclusion: Subcutaneous docetaxel achieves lymphatic accumulation greater than that of i.v. delivery.

Original languageEnglish (US)
Pages (from-to)5071-5078
Number of pages8
JournalAnticancer Research
Volume36
Issue number10
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

docetaxel
Lymph
Carboplatin
Thoracic Duct
Jugular Veins
Catheterization
Half-Life
Rodentia
Pharmacokinetics

Keywords

  • Carboplatin pharmacokinetics
  • Docetaxel pharmacokinetics
  • Lymph
  • Subcutaneous administration

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Docetaxel accumulates in lymphatic circulation following subcutaneous delivery compared to intravenous delivery in rats. / Worley, Deanna R.; Hansen, Ryan J.; Wittenburg, Luke Anthony; Chubb, Laura S.; Gustafson, Daniel L.

In: Anticancer Research, Vol. 36, No. 10, 01.10.2016, p. 5071-5078.

Research output: Contribution to journalArticle

Worley, Deanna R. ; Hansen, Ryan J. ; Wittenburg, Luke Anthony ; Chubb, Laura S. ; Gustafson, Daniel L. / Docetaxel accumulates in lymphatic circulation following subcutaneous delivery compared to intravenous delivery in rats. In: Anticancer Research. 2016 ; Vol. 36, No. 10. pp. 5071-5078.
@article{6334b4d676e54bd4a6d254e54a85a432,
title = "Docetaxel accumulates in lymphatic circulation following subcutaneous delivery compared to intravenous delivery in rats",
abstract = "Background: The circulatory pathway for particles deposited outside of blood capillaries has not been well characterized for non-traditionally-delivered chemotherapeutics. Materials and Methods: Blood and lymph pharmacokinetics of docetaxel (5 mg/kg) and carboplatin (14 and 28 mg/kg) following subcutaneous (s.c.) versus intravenous (i.v.) delivery were determined in a rodent model with catheterizations of both the thoracic lymphatic duct and jugular vein for prolonged synchronous blood and lymph sampling. Results: Subcutaneous docetaxel demonstrates preferential lymphatic accumulation based on the area under the time-concentration curve (AUC0-24h) whereas i.v. docetaxel resulted in a greater plasma maximum concentration measured (Cmax). The apparent elimination half-life (t1/2) in lymph for docetaxel is greater following i.v. or s.c. delivery compared to t1/2 in blood. Carboplatin demonstrates a dose-dependent increase in plasma Cmax regardless of delivery route; the total carboplatin exposure over 24 h in lymph and plasma are comparable. Conclusion: Subcutaneous docetaxel achieves lymphatic accumulation greater than that of i.v. delivery.",
keywords = "Carboplatin pharmacokinetics, Docetaxel pharmacokinetics, Lymph, Subcutaneous administration",
author = "Worley, {Deanna R.} and Hansen, {Ryan J.} and Wittenburg, {Luke Anthony} and Chubb, {Laura S.} and Gustafson, {Daniel L.}",
year = "2016",
month = "10",
day = "1",
doi = "10.21873/anticanres.11076",
language = "English (US)",
volume = "36",
pages = "5071--5078",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Docetaxel accumulates in lymphatic circulation following subcutaneous delivery compared to intravenous delivery in rats

AU - Worley, Deanna R.

AU - Hansen, Ryan J.

AU - Wittenburg, Luke Anthony

AU - Chubb, Laura S.

AU - Gustafson, Daniel L.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background: The circulatory pathway for particles deposited outside of blood capillaries has not been well characterized for non-traditionally-delivered chemotherapeutics. Materials and Methods: Blood and lymph pharmacokinetics of docetaxel (5 mg/kg) and carboplatin (14 and 28 mg/kg) following subcutaneous (s.c.) versus intravenous (i.v.) delivery were determined in a rodent model with catheterizations of both the thoracic lymphatic duct and jugular vein for prolonged synchronous blood and lymph sampling. Results: Subcutaneous docetaxel demonstrates preferential lymphatic accumulation based on the area under the time-concentration curve (AUC0-24h) whereas i.v. docetaxel resulted in a greater plasma maximum concentration measured (Cmax). The apparent elimination half-life (t1/2) in lymph for docetaxel is greater following i.v. or s.c. delivery compared to t1/2 in blood. Carboplatin demonstrates a dose-dependent increase in plasma Cmax regardless of delivery route; the total carboplatin exposure over 24 h in lymph and plasma are comparable. Conclusion: Subcutaneous docetaxel achieves lymphatic accumulation greater than that of i.v. delivery.

AB - Background: The circulatory pathway for particles deposited outside of blood capillaries has not been well characterized for non-traditionally-delivered chemotherapeutics. Materials and Methods: Blood and lymph pharmacokinetics of docetaxel (5 mg/kg) and carboplatin (14 and 28 mg/kg) following subcutaneous (s.c.) versus intravenous (i.v.) delivery were determined in a rodent model with catheterizations of both the thoracic lymphatic duct and jugular vein for prolonged synchronous blood and lymph sampling. Results: Subcutaneous docetaxel demonstrates preferential lymphatic accumulation based on the area under the time-concentration curve (AUC0-24h) whereas i.v. docetaxel resulted in a greater plasma maximum concentration measured (Cmax). The apparent elimination half-life (t1/2) in lymph for docetaxel is greater following i.v. or s.c. delivery compared to t1/2 in blood. Carboplatin demonstrates a dose-dependent increase in plasma Cmax regardless of delivery route; the total carboplatin exposure over 24 h in lymph and plasma are comparable. Conclusion: Subcutaneous docetaxel achieves lymphatic accumulation greater than that of i.v. delivery.

KW - Carboplatin pharmacokinetics

KW - Docetaxel pharmacokinetics

KW - Lymph

KW - Subcutaneous administration

UR - http://www.scopus.com/inward/record.url?scp=84991769632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991769632&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11076

DO - 10.21873/anticanres.11076

M3 - Article

VL - 36

SP - 5071

EP - 5078

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -